(Q38345974)

2 September 2017

1 reference

title

Bcr-Abl tyrosine kinase inhibitors: a patent review (English)

1 reference

2 September 2017

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

author name string

Andrea Desogus

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Silvia Schenone

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Chiara Brullo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

Cristina Tintori

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

language of work or name

English

0 references

publication date

6 February 2015

1 reference

Expert Opinion on Therapeutic Patents

2 September 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

volume

25

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

1 June 2020

page(s)

397-412

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25656651%20AND%20SRC:MED&resulttype=core&format=json

ABL Tyrosine Kinases: Evolution of Function, Regulation, and Specificity

1 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Structure and dynamic regulation of Abl kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Structural basis for the autoinhibition of c-Abl tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

A myristoyl/phosphotyrosine switch regulates c-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Targeting cancer with small molecule kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Proteus in the world of proteins: conformational changes in protein kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

How I treat chronic myeloid leukemia in the imatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

New opportunities to treat the T315I-Bcr-Abl mutant in chronic myeloid leukaemia: tyrosine kinase inhibitors and molecules that act by alternative mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Resistance to imatinib mesylate in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Tyrosine kinase inhibitors in acute and chronic leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

New insights into small-molecule inhibitors of Bcr-Abl

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

BCR-ABL inhibitors: updates in the management of patients with chronic-phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Conformational Control Inhibition of the BCR-ABL1 Tyrosine Kinase, Including the Gatekeeper T315I Mutant, by the Switch-Control Inhibitor DCC-2036

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Danusertib, an aurora kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Ever-advancing chronic myeloid leukemia treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Chronic myeloid leukemia: overview of new agents and comparative analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Using insights into Pim1 structure to design new anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Axitinib in the treatment of metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155

Vascular endothelial growth factor (VEGF) receptors: drugs and new inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2015.1012155